Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
about
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancerClinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancerSrc mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma modelsThe impact of microRNA-mediated PI3K/AKT signaling on epithelial-mesenchymal transition and cancer stemness in endometrial cancer.Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.Lactate dehydrogenase A negatively regulated by miRNAs promotes aerobic glycolysis and is increased in colorectal cancer.Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancerPredictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.Single nucleotide polymorphisms in microRNA binding sites of oncogenes: implications in cancer and pharmacogenomics.MicroRNAs targeting EGFR signalling pathway in colorectal cancer.miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma.Noncoding RNAs in Therapeutic Resistance of Cancer.Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer.Involvement of Non-coding RNAs in the Signaling Pathways of Colorectal Cancer.MicroRNAs as Regulator of Signaling Networks in Metastatic Colon Cancer.Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma.Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.A tRNA fragment, tRF5-Glu, regulates BCAR3 expression and proliferation in ovarian cancer cells.The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy.Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies.FIBP knockdown attenuates growth and enhances chemotherapy in colorectal cancer via regulating GSK3β-related pathways
P2860
Q26775610-172C7414-E65F-4307-8C61-80C0A6DF5109Q27024235-33F75A2D-FCA4-4F69-8615-F701075B445FQ28544422-EACC2031-7036-47E7-AD49-13C738703162Q34091442-12286302-059E-4B32-B4A8-994971687BDBQ35149263-EADAA84F-1237-4C7B-9AD3-9C131DAED4C1Q36260554-0D23299F-1A80-4152-9C74-15450A40E0BBQ36530668-E1FD2E84-B226-4BA6-B5A2-AFC139B2A915Q37360360-BB6535EC-6F1E-44E3-9FF3-0A06A4F9DD74Q37577068-B150A599-9E40-40F9-9E5D-CEACC0530E89Q38118612-1AFB63B0-7430-42CA-8D7A-4DC4F9C792F8Q38138933-82A15CA7-5B9B-4B46-87F7-AD2E96DC3A9AQ38885495-6155E244-51CE-4FEB-9E22-D30A397BC4CFQ38932418-43DCC44F-9E70-4E3B-9809-C15925A77C07Q38940586-7039AA40-C356-4FA2-9C1C-847EBB0B4FD7Q40864983-7B8B3141-4E2F-4DB2-BAAF-BD831D19ADC1Q41574276-57100E3E-BD25-47D9-A326-6E8BFC6D54FFQ43806776-004068F1-28FE-47B1-A9EF-3571E2D3473DQ47136784-E5B49512-77F0-4FF6-B944-E6FFCFADA06BQ50017359-9B94B65D-ACBA-444D-9C4A-DE867B00B1D4Q53765363-CEAB2DF8-FC44-4764-9695-D4C3A76B3AC5Q57049171-5276B3A5-D213-4629-9268-3DB1CD0E8105
P2860
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@en
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@nl
type
label
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@en
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@nl
prefLabel
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@en
Common PIK3CA mutants and a no ...... ed sensitivity to saracatinib.
@nl
P2093
P2860
P1476
Common PIK3CA mutants and a no ...... sed sensitivity to saracatinib
@en
P2093
Anna Spreafico
Arvind Dasari
Basel M Touban
Jaclyn M Reinemann
John J Arcaroli
Kevin S Quackenbush
Marileila Varella-Garcia
Rebecca W Powell
S Gail Eckhardt
Todd M Pitts
P2860
P304
P356
10.1158/1078-0432.CCR-11-3167
P407
P577
2012-05-01T00:00:00Z